VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Fundamental Analysis
FRA:VX1 - Deutsche Boerse Ag - US92532F1003 - Common Stock - Currency: EUR
VX1 gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 72 industry peers in the Biotechnology industry. While VX1 has a great health rating, its profitability is only average at the moment. VX1 has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year VX1 has reported negative net income.
In the past year VX1 has reported a negative cash flow from operations.
VX1 had positive earnings in 4 of the past 5 years.
VX1 had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
VX1 has a Return On Assets of -4.32%. This is in the better half of the industry: VX1 outperforms 65.28% of its industry peers.
VX1 has a better Return On Equity (-5.99%) than 69.44% of its industry peers.
The Return On Invested Capital of VX1 (15.51%) is better than 91.67% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for VX1 is above the industry average of 12.56%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.32% | ||
| ROE | -5.99% | ||
| ROIC | 15.51% |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.35%
ROIC(5y)17.95%
1.3 Margins
With an excellent Operating Margin value of 37.91%, VX1 belongs to the best of the industry, outperforming 93.06% of the companies in the same industry.
In the last couple of years the Operating Margin of VX1 has grown nicely.
Looking at the Gross Margin, with a value of 86.03%, VX1 belongs to the top of the industry, outperforming 80.56% of the companies in the same industry.
VX1's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 37.91% | ||
| PM (TTM) | N/A | ||
| GM | 86.03% |
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
2. Health
2.1 Basic Checks
VX1 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, VX1 has less shares outstanding
Compared to 5 years ago, VX1 has less shares outstanding
The debt/assets ratio for VX1 has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 13.31 indicates that VX1 is not in any danger for bankruptcy at the moment.
VX1's Altman-Z score of 13.31 is amongst the best of the industry. VX1 outperforms 91.67% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that VX1 is not too dependend on debt financing.
VX1 has a Debt to Equity ratio of 0.01. This is amongst the best in the industry. VX1 outperforms 83.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 13.31 |
ROIC/WACC1.59
WACC9.75%
2.3 Liquidity
VX1 has a Current Ratio of 2.65. This indicates that VX1 is financially healthy and has no problem in meeting its short term obligations.
VX1's Current ratio of 2.65 is fine compared to the rest of the industry. VX1 outperforms 61.11% of its industry peers.
A Quick Ratio of 2.29 indicates that VX1 has no problem at all paying its short term obligations.
VX1's Quick ratio of 2.29 is fine compared to the rest of the industry. VX1 outperforms 61.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.65 | ||
| Quick Ratio | 2.29 |
3. Growth
3.1 Past
The earnings per share for VX1 have decreased strongly by -102.42% in the last year.
Measured over the past years, VX1 shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -44.14% on average per year.
Looking at the last year, VX1 shows a quite strong growth in Revenue. The Revenue has grown by 8.98% in the last year.
VX1 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.50% yearly.
EPS 1Y (TTM)-102.42%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%-14.71%
Revenue 1Y (TTM)8.98%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%2.96%
3.2 Future
Based on estimates for the next years, VX1 will show a very strong growth in Earnings Per Share. The EPS will grow by 152.83% on average per year.
Based on estimates for the next years, VX1 will show a quite strong growth in Revenue. The Revenue will grow by 10.19% on average per year.
EPS Next Y6211.74%
EPS Next 2Y753.07%
EPS Next 3Y332.19%
EPS Next 5Y152.83%
Revenue Next Year9.56%
Revenue Next 2Y10.19%
Revenue Next 3Y9.82%
Revenue Next 5Y10.19%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VX1. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 22.47 indicates a rather expensive valuation of VX1.
Based on the Price/Forward Earnings ratio, VX1 is valued cheaper than 81.94% of the companies in the same industry.
VX1's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 37.13.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 22.47 |
4.2 Price Multiples
VX1's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. VX1 is cheaper than 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 25.45 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of VX1 may justify a higher PE ratio.
A more expensive valuation may be justified as VX1's earnings are expected to grow with 332.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y753.07%
EPS Next 3Y332.19%
5. Dividend
5.1 Amount
No dividends for VX1!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:VX1 (7/30/2025, 7:00:00 PM)
411.15
+6.4 (+1.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners97.73%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap105.58B
Analysts75
Price Target445.85 (8.44%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.13%
Min EPS beat(2)-7.2%
Max EPS beat(2)-3.07%
EPS beat(4)1
Avg EPS beat(4)-133.54%
Min EPS beat(4)-527.57%
Max EPS beat(4)3.69%
EPS beat(8)4
Avg EPS beat(8)-65%
EPS beat(12)7
Avg EPS beat(12)-42.16%
EPS beat(16)10
Avg EPS beat(16)-29.51%
Revenue beat(2)1
Avg Revenue beat(2)-1.06%
Min Revenue beat(2)-4.8%
Max Revenue beat(2)2.68%
Revenue beat(4)1
Avg Revenue beat(4)-1.23%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.75%
Revenue beat(12)5
Avg Revenue beat(12)-0.37%
Revenue beat(16)8
Avg Revenue beat(16)0.2%
PT rev (1m)-0.27%
PT rev (3m)-0.38%
EPS NQ rev (1m)-0.64%
EPS NQ rev (3m)-1.95%
EPS NY rev (1m)-0.11%
EPS NY rev (3m)-0.84%
Revenue NQ rev (1m)-0.03%
Revenue NQ rev (3m)-0.24%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)-0.32%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 22.47 | ||
| P/S | 10.97 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 7.38 | ||
| P/tB | 8.14 | ||
| EV/EBITDA | 25.45 |
EPS(TTM)-0.36
EYN/A
EPS(NY)18.3
Fwd EY4.45%
FCF(TTM)-4.25
FCFYN/A
OCF(TTM)-3.31
OCFYN/A
SpS37.48
BVpS55.7
TBVpS50.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.32% | ||
| ROE | -5.99% | ||
| ROCE | 22.04% | ||
| ROIC | 15.51% | ||
| ROICexc | 22.97% | ||
| ROICexgc | 26.06% | ||
| OM | 37.91% | ||
| PM (TTM) | N/A | ||
| GM | 86.03% | ||
| FCFM | N/A |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.35%
ROIC(5y)17.95%
ROICexc(3y)45.4%
ROICexc(5y)50.15%
ROICexgc(3y)65.51%
ROICexgc(5y)78.06%
ROCE(3y)24.64%
ROCE(5y)25.5%
ROICexcg growth 3Y-26.3%
ROICexcg growth 5Y-6.95%
ROICexc growth 3Y-19.26%
ROICexc growth 5Y0.61%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score4
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.03 | ||
| Cap/Depr | 137.41% | ||
| Cap/Sales | 2.5% | ||
| Interest Coverage | 181.38 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.65 | ||
| Quick Ratio | 2.29 | ||
| Altman-Z | 13.31 |
F-Score4
WACC9.75%
ROIC/WACC1.59
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.84%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-102.42%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%-14.71%
EPS Next Y6211.74%
EPS Next 2Y753.07%
EPS Next 3Y332.19%
EPS Next 5Y152.83%
Revenue 1Y (TTM)8.98%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%2.96%
Revenue Next Year9.56%
Revenue Next 2Y10.19%
Revenue Next 3Y9.82%
Revenue Next 5Y10.19%
EBIT growth 1Y-1.84%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year827.23%
EBIT Next 3Y131%
EBIT Next 5Y70.83%
FCF growth 1Y-132.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-124.06%
OCF growth 3YN/A
OCF growth 5YN/A